Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
76-90 of 4468 results
Takeda, NuBiyota to collaborate on microbiome therapeutics
Takeda Pharmaceutical has partnered with NuBiyota to develop Microbial Ecosystem Therapeutic products for gastroenterology (GI) conditions.
Drug Research > Drug Discovery & Development > News
Immune-Onc to partner with University of Texas on novel cancer immunotherapy
Immune-Onc Therapeutics has signed an exclusive license and collaboration agreement with The University of Texas Health Science Center at Houston (“UTHealth”) and The University of Texas Southwestern Medical Center (“UTSW”), two member institutions of The University of Texas System (“UT System”).
Drug Research > Drug Discovery & Development > News
Eisai and Meiji enter into agreement for Parkinson's disease drug in Asian countries
Eisai and Meiji Seika Pharma have entered into a license agreement for the commercialization of safinamide for Parkinson's disease treatment in Japan and Asia.
Drug Research > Drug Discovery & Development > News
Finch and Takeda to jointly develop microbiome therapeutics in IBD
Microbiome engineering company, Finch Therapeutics and Takeda Pharmaceutical have reached a global collaboration agreement for the joint development of FIN-524.
Drug Research > Drug Discovery & Development > News
Aviragen Therapeutics to explore strategic alternatives
Aviragen Therapeutics intends to explore a range of strategic alternatives including a business combination, merger, in-licensing of complementary products, acquisition or any other value-building transaction.
Drug Research > Drug Discovery & Development > News
Sucampo Pharmaceuticals buys rare disease firm Vtesse
Sucampo Pharmaceuticals has acquired rare disease company Vtesse for upfront consideration of $200m.
Drug Research > Drug Discovery & Development > News
Verona Pharma announces new collaborations to develop dry powder and MDI formulations for COPD
Verona Pharma has announced new collaborations with two European technology companies to develop its first-in-class product candidate RPL554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Drug Research > Drug Discovery & Development > News
Warp Drive Bio forms technology alliance with GSK
Warp Drive Bio has partnered with GSK to discover potential therapeutics in oncology and other diseases.
Drug Research > Drug Discovery & Development > News
University of Dundee secures grant to discover new antibacterial drugs
University of Dundee in the UK has been awarded almost £1m to boost efforts to identify new new antibiotics to tackle bacterial infections.
Drug Research > Drug Discovery & Development > News
Ignyta to explore strategic options for cancer candidate taladegib
Ignyta is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly and Company for the taladegib oncology program.
Drug Research > Drug Discovery & Development > News
BioLineRx acquires UK cancer immunotherapeutics company Agalimmune
Clinical-stage biopharmaceutical firm BioLineRx has purchased Agalimmune, a private UK-based company with an anti-cancer immunotherapy platform.
Drug Research > Drug Discovery & Development > News
GSK, Regeneron to mine gene data from 500000 volunteer participants in UK
Regeneron Pharmaceuticals announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource.
Drug Research > Drug Discovery & Development > News
Pierre Fabre, H-Immune partner on immuno-oncology therapeutics
French pharma Pierre Fabre has entered into a strategic research partnership with H-Immune to develop immuno-oncology therapeutics using the latter’s technology platform to generate lead candidates of fully human antibodies.
Drug Research > Drug Discovery & Development > News
X-Chem, Ono to collaborate on multi-target drug discovery
X-Chem, a biotechnology firm focused on developing novel small molecule therapeutics by applying its innovative drug discovery platform, has entered into a partnership with Ono Pharmaceutical.
Drug Research > Drug Discovery & Development > News
SalvaRx to invest in Rift Biotherapeutics
SalvaRx, a subsidiary of SalvaRx Group, has agreed to invest in Delaware-based biotechnology company Rift Biotherapeutics which focuses on the development of antibodies for use in oncology.
Drug Research > Drug Discovery & Development > News
76-90 of 4468 results